TMO Earnings Date: Feb 4, 2027 (Estimated) — Thermo Fisher Scientific Inc.
NYSE · Healthcare · Diagnostics & Research
Updated
When is TMO's next earnings date?
Thermo Fisher Scientific Inc. (TMO) is expected to report Q4 2026 earnings on Thursday, February 4, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $7.27 on revenue of $12.90B.
How did TMO do in its last earnings report?
In its most recent report on Oct 21, 2026 (Q3 2026), Thermo Fisher Scientific Inc. posted EPS of $6.68 versus the $6.41 estimate, a beat of 4.2%. Revenue was $12.14B against a $11.95B estimate. The stock's 1-day post-earnings move was +1.0%.
How much does TMO stock move after earnings?
TMO beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.0% (up or down) in the day after earnings.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
🤖 AI Earnings Analysis
Thermo Fisher delivered a strong, broad-based quarter, with revenue up 9% to $12.1B and EPS of $6.68 beating estimates by $0.27. The diagnostics and research leader’s full-year outlook is $47.4B–$48.1B revenue and $24.93–$25.33 EPS.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 | Q3 2026 | 6.41 | 6.68 | +4.21% | $12.14B | ✅ Beat | +0.97% | +0.82% | — |
| 2026-07-23 | Q2 2026 | 5.71 | 6.03 | +5.60% | $11.99B | ✅ Beat | +8.71% | +9.50% | +19.20% |
| 2026-04-23 | Q1 2026 | 5.23 | 5.44 | +4.02% | $11.01B | ✅ Beat | -9.20% | -9.28% | -12.57% |
| 2026-01-29 | Q4 2025 | 6.44 | 6.57 | +2.02% | $12.21B | ✅ Beat | -2.61% | -7.04% | -14.29% |
| 2025-10-22 | Q3 2025 | 5.50 | 5.79 | +5.27% | $11.12B | ✅ Beat | +1.65% | -0.06% | +2.83% |
| 2025-07-23 | Q2 2025 | 5.23 | 5.36 | +2.49% | $10.86B | ✅ Beat | +9.14% | +12.75% | +15.71% |
| 2025-04-23 | Q1 2025 | 5.10 | 5.15 | +0.98% | $10.36B | ✅ Beat | -0.71% | -1.66% | -8.38% |
| 2025-01-30 | Q4 2024 | 5.94 | 6.10 | +2.69% | $11.39B | ✅ Beat | +6.78% | +2.49% | -6.91% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $11.99B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product revenues | 56.9% | $6.82B | — | — | — | — | — |
| Services | 43.1% | $5.17B | — | — | — | — | — |
By region
Q2 FY26 · $11.99B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 51.3% | $6.15B | +7.5% | $5.87B | $5.51B | $5.72B | $5.69B |
| Europe | 27.6% | $3.31B | +17.0% | $2.89B | $2.62B | $2.83B | $3.00B |
| Asia Pacific | 17.5% | $2.10B | +9.6% | $2.20B | $1.89B | $1.92B | $2.01B |
| All Other Countries | 3.6% | $430.0M | +12.3% | $439.0M | $337.0M | $383.0M | $415.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.